The Impact of Targeting KIT Mutations with Imatinib in Gastrointestinal Stromal Tumors: A Review of a Therapeutic Revolution

Abstract

Introduction: Gastrointestinal Stromal Tumors (GISTs) are rare mesenchymal tumors that were historically highly resistant to conventional chemotherapy, resulting in a poor prognosis for patients with advanced disease. A fundamental breakthrough was the discovery that most GISTs are driven by activating mutations in the KIT receptor tyrosine kinase.

Literature Review: A review of the pivotal literature chronicles a rapid and complete paradigm shift in the management of this disease. The discovery of the central role of KIT mutations provided a clear molecular target for the tyrosine kinase inhibitor, imatinib. Initial, groundbreaking clinical trials in patients with metastatic GIST demonstrated unprecedented and dramatic rates of clinical response, with the vast majority of patients achieving either significant tumor shrinkage or durable disease stabilization. Large, randomized phase III trials subsequently confirmed the profound survival benefit of imatinib, extending median survival from less than a year to several years. This success was extended to the curative-intent setting, where a landmark adjuvant trial showed that imatinib therapy after surgery significantly reduced the risk of tumor recurrence in patients with high-risk GIST.

Conclusion: The body of evidence unequivocally established targeted therapy with imatinib as the standard of care for KIT-positive GIST. This research transformed a once untreatable solid tumor into a chronically manageable, and sometimes curable, condition, serving as a quintessential example of the success of molecularly guided cancer therapy.